Given that multiple sclerosis (MS) is an autoimmune disease whose first phase involves inflammatory processes with perivascular infiltration of lymphocytes and macrophages associated with demyelinization, immunomodulating drugs should be used for treatment. The action of these drugs is basically anti-inflammatory, and they are used to delay or stop the disease progression.
As explained in the previous articles, patients who at diagnosis undergo an isolated demyelinating process and have more than three lesions revealed through magnetic resonance imaging (MRI) are more likely to progress to clinically definite MS (CDMS) within 10 years . Patients would benefit from early immunomodulating treatment, soon after its first clinical manifestations, delaying the disease progression and decreasing the degree of disability and the brain lesions typical.
Autor: Dr. Fernando Caceres